VivoSeq
Oncology

Metastatic Non Small Cell Lung Cancer

11

Pipeline Programs↗

6

Active Trials↗

9

Companies Involved↗

Metastatic Non Small Cell Lung Cancer is an emerging landscape with 11 programs across 9 companies. The most active players are Iovance Biotherapeutics, Inc., Daiichi Sankyo, Merck & Co.. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3A

Avyxa

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

70%

Small molecule

7 of 10 classified programs — the dominant modality here.

30%ALL OTHERSMonoclonal antibody110%Antibody–drug conjugate110%Cell therapy110%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 91% of 11 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting5 · 83%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
Recruiting·CCentre Hospitalier Universitaire Dijon·N/A·NCT05985330·56 enrolled
A Single-Center, Prospective, Open-Label, Investigator-Initiated Study Evaluating the Safety, Biodistribution, Radiation Dosimetry, and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07689643·36 enrolled
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer
Recruiting·IIovance Biotherapeutics, Inc.·Phase 2·NCT04614103·170 enrolled
A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Preclinical·NCT07063745·590 enrolled
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Recruiting·NNovoCure GmbH·Phase 3·NCT06216301·734 enrolled
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
Active, not recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 3·NCT05555732·1,170 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)